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Abstract: Metabolic syndrome, a cluster of different disorders which include diabetes, obesity and
cardiovascular diseases, is a global epidemic that is growing at an alarming rate. The origins of disease
can be traced back to early developmental stages of life. This has increased mortalities and continues
to reduce life expectancies of individuals across the globe. The aim of this study was to investigate
the sub-acute and long term effects of neonatal oral administration of oleanolic acid and metformin
on lipids (free fatty acids, FFAs) and genes associated with lipid metabolism and glucose transport
using a neonatal rat experimental model. In the first study, seven days old pups were randomly
grouped into control—distilled water (DW); oleanolic acid (60 mg/kg), metformin (500 mg/kg),
high fructose diet (20% w/v, HF), oleanolic acid (OA) + high fructose diet (OA + HF), and Metformin
+ high fructose diet (MET + HF) groups. The pups were treated for 7 days, and then terminated on
postnatal day (PD) 14. In the second study, rat pups were initially treated similarly to study 1 and
weaned onto normal rat chow and plain drinking water on PD 21 till they reached adulthood (PD112).
Tissue and blood samples were collected for further analyses. Measurement of the levels of free
fatty acids (FFAs) was done using gas chromatography-mass spectrometry. Quantitative polymerase
chain reaction (qPCR) was used to analyze the gene expression of glut-4, glut-5, fas, acc-1, nrf-1 and
cpt-1 in the skeletal muscle. The results showed that HF accelerated accumulation of saturated FFAs
within skeletal muscles. The HF fed neonatal rats had increased stearic acid, which was associated
with decreased glucose, suppressed expression of glut-4, glut-5, nrf-1 and cpt-1 genes, and increased
expression of acc-1 (p < 0.01) and fas. OA + HF and MET + HF treated groups had increased mono- and
polyunsaturated FFAs; oleic, and octadecadienoic acids than the HF group. These unsaturated FFAs
were associated with increased glut-4, glut-5 and nrf-1 (p < 0.01) and decreased acc-1 and fas (p < 0.05)
in both OA + HF and MET + HF treated groups. Conclusions: The present study shows that neonatal
oral administration of oleanolic acid and metformin potentially protects against the development of
fructose-induced metabolic dysfunction in the rats in both short and long time periods.
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1. Introduction
The World Health Organization (WHO) has indicated that the world’s population living with
obesity has doubled to 13% since the 1980s, affecting more than 600 million adults and 42 million
children under the age of 5 years in 2014 [1]. This indicates that obesity has become a global epidemic
that is growing at an alarming rate. As a risk factor to metabolic syndrome, obesity results in high
mortalities both in children and adults, and continues to reduce life expectancies of individuals
across the globe [2]. Metabolic syndrome occurs when there is a disruption of metabolic functions in
which essential substances such as hormones, enzymes, proteins, or genes are expressed or produced
in low or high concentrations in the body causing the metabolic network to fail [3,4]. This means
that metabolic syndrome occurs when there are abnormalities in the metabolic system. Initially,
interventions in lifestyle including adopting a healthy diet, increasing physical activity and weight
loss were recommended as the most effective mitigation of obesity and metabolic syndrome [5].
However, in some cases, even when individuals manage to lose weight, they still continue to suffer
from metabolic syndrome. Obesity is the sixth most lethal risk factor contributing to a number of
metabolic diseases [1,6]. Obesity is a complicated condition which is not easy to mitigate, as it is not
only caused by excess food intake and comparatively less energy expenditure, but complex metabolic
disruptions that are centered on lipid metabolism and cellular signaling systems linked to it [7].
Pharmacotherapy has been recommended as an effective way to counter metabolic syndrome
associated with obesity [5]. However, it has been reported that most pharmacological anti-obesity drugs
which also tend to be expensive, have side effects such as altering blood pressure, headaches, dizziness
and other unbearable collateral effects that adversely affect the quality of life [2]. There is a growing
need for less costly, effective anti-obesity agents that have minimal collateral effects. Phytochemicals
are increasingly being explored for their therapeutic potential. An example of such is oleanolic acid
(3β-hydroxy-olean-12-en-28-oic acid), which is a natural, bioactive phytochemical component found in
several plant foods and medicinal herbs [8,9]. It is a pentacyclic triterpenoid that is found in abundance
in plants of the Oleaceae family such as the olive plant and also occurs in nature as a free acid or as an
aglycone of triterpenoid saponins [10]. It is biosynthesized by the acetate/mevalonate pathway and
(3S)-2,3-oxidosqualene cyclization [8].
Metformin is a widely used pharmaceutical drug for treating components of metabolic
syndrome, and was discovered five decades ago [11]. It is an orally administered anti-diabetic
drug from the biguanide class, which has been proven to reduce plasma insulin, glucose, FFAs and
overall body weight in diabetic and obese patients [12]. Oleanolic acid and metformin exhibit
several pharmacological properties such as antioxidant, microbicide, antidiabetic, anti-inflammatory,
hypolipidaemic antiatherosclerotic and anti-cancer actions [8,9,11,13]. The neonatal period is a phase
of life with developmental plasticity wherein interventions have long term impacts on the health and
disease outcomes of individuals. Hence, the aim of this study was to examine the sub-acute and long
term potential protective effects of neonatal oral administration of oleanolic acid and metformin against
fructose-induced alterations in the level of lipids (free fatty acids, FFAs) and impaired expression of
genes associated with lipid metabolism and glucose transport using a rat model.
2. Results
2.1. Growth Development of the Rats
In the first study, there was a significant increase in body mass from the induction of treatments
(PD7) up to termination across all treatment groups (p < 0.05; Table 1). There were no significant
differences across all treatment groups at induction and termination (p > 0.001).
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Table 1. Study 1 weight of the rats during the neonatal developmental stage (day 1 to day 14), presented
in mean (g) ± SD.
Experimental Groups Induction Body Mass (g) Terminal Body Mass (g)
DW 15.11 ± 1.54 17.01 ± 1.71
OA 16.60 ± 1.22 18.60 ± 0.86
MET 15.79 ± 1.42 16.75 ± 1.85
HF 16.46 ± 1.42 18.15 ± 1.31
OA + HF 16.14 ± 2.26 17.78 ± 2.52
MET + HF 16.24 ± 1.96 17.01 ± 1.71
In the second study, the rats grew significantly from induction at PD7, to weaning PD21 and
subsequently to termination age PD112 (p < 0.05; Figure 1). The rats that received fructose in the
neonatal phase and adulthood had significantly higher terminal body masses compared to the other
treatment groups (p < 0.05; Figure 1). Oleanolic acid and MET treatment in the neonatal period (OA,
MET, OA + HF and MET + HF) attenuated the fructose induced increase in terminal body mass
(p < 0.05; Figure 1). Moreover, there was no distinct significant difference in visceral fat mass between
the control and OA, MET, OA + HF and MET + HF (Figure 2). However, there was a significant
difference between the control and the HF group (p < 0.05; Figure 2).
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Figure 2. The effect of neonatal oral administration of oleanolic acid and metformin on visceral fat 
mass in female rats fed a high fructose diet. All experimental groups were compared with the control 
(DW); HF p < 0.05 (*) (n = 8). 
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2.2. Saturated Free Fatty Acid
In the sub-acute study (Experiment 1), the levels of stearic acid were significantly higher in the
group that was treated with fructose (HF) compared to the other treatment groups (p < 0.05; Table 2).
Neonatal OA and MET treatment prevented the fructose induced increase in stearic acid (p < 0.05;
Table 2). In the long term study (Experiment 2), stearic acid levels were 5-fold higher in the rats that
received HF compared to treatment groups (p < 0.05; Table 2). Neonatal oral administration of OA and
MET prevented the fructose induced increase in stearic acid (p < 0.01; Table 2).
Table 2. The response factor (Ra) of stearic acid in both sub-acute (study 1) and long term (study 2) of
the experiment.
Experimental Gr ups Study 1 (Mean± SD) Study 2 (Mean± SD)
DW 2.30 ± 1.72 1.29 ± 0.77
OA 1.01 ± 1.04 0.75 ± 0.89 *
MET 0.75 ± 0.89 * 0.38 ± 0.23 **
HF 4.70 ± 7.19 * 1.92 ± 1.31 *
OA + HF 0.56 ± 0.48 ** 0.37 ± 0.17 **
MET + HF 0.24 ± 0.19 *** 0.20 ± 0.16 ***
Data of the stearic acid response factor (Ra) were calculated in R statistics and presented as mean ± sd (n = 5).
Student’s t-test for phase 1, MET versus DW (control) p < 0.05 (*), HF versus DW p < 0.05 (*), OA + HF versus DW
p < 0.01 (**) and MET + HF versus DW p < 0.001 (***).In phase 2, OA versus DW p < 0.05 (*), MET versus DW p < 0.01
(**), HF versus DW p < 0.05 (*), OA + HF versus DW p < 0.01 (**) and MET + HF versus DW p < 0.001 (***).
The stearic acid response factor was lower in all long term (study 2) experimental groups than that
of the sub-acute study (Table 2). However, only the control groups and the HF groups were statistically
signific nt (DW p < 0.05 and HF p < 0.01). Moreover, there was no statistical sig ificant difference in
the overall response fac or of acid from both experiments 1 and 2. Stearic acid was higher in the HF
group, which is the group where obesity/metabolic dysfunctions were induced. The e uggest that
HF promotes accum lation of saturated fre fatty acids in the body.
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2.3. Monounsaturated Free Fatty Acids
In Study 1, oleic acid was significantly higher in the OA (1.55 ± 1.03; p < 0.001) and OA + HF
group (0.09 ± 0.08; p < 0.05) compared to the other treatment groups. Oleic acid was not detected from
the control group, MET, HF and MET + HF.
In Study 2, oleic acid was not detected in the control group and the HF group (Table 3). However, it
was detected in the OA (1.39± 0.26), MET (0.67± 0.47), OA + HF (0.17± 0.03) and the MET + HF (0.06
± 0.03) groups. The OA, MET and OA + HF groups were significantly different from the control group
(OA p < 0.001, MET p < 0.001 and OA + HF p < 0.05). Moreover, OA (1.39 ± 0.26) and MET (0.67 ±
0.47) groups had high data dispersions than the OA + HF group (0.17 ± 0.03) (Table 3). Oleic acid was
higher in both the OA and the OA + HF groups (Table 3). The MET group was the only group that
was significantly different between experiment 1 and 2 (p < 0.001). Oleic acid was not detected in the
sub-acute study rats of the MET group and MET + HF group, but it was detected in the groups of the
long term experiment rats. The response factor of oleic acid from all samples of both sub-acute and
long term experiments was statistically significantly different (p < 0.01). Both in study 1 and 2 of the
experiment, oleic acid was prominent in the OA and OA + HF groups.
Table 3. The response factor of oleic acid in the rats from the sub-acute and long term experiments.
Experimental Groups Study 1 (Mean (Ra)± SD) Study 2 (Mean (Ra)± SD)
DW 0.00 ± 0.00 0.00 ± 0.00
OA 1.55 ± 1.03*** 1.39 ± 0.26***
MET 0.00 ± 0.00 0.67 ± 0.47***
HF 0.00 ± 0.00 0.00 ± 0.00
OA + HF 0.09 ± 0.08* 0.17 ± 0.03*
MET + HF 0.00 ± 0.00 0.06 ± 0.03
Data of the oleic acid response factor (Ra) were calculated in R statistics and presented as mean± sd (n = 5). In phase
1, student’s t-test results for OA versus DW p < 0.001 (***) and OA + HF versus DW p < 0.05 (*). In phase 2, OA
versus DW p < 0.001 (***), MET versus DW p < 0.001 (***) and OA + HF versus DW p < 0.05 (*).
2.4. Polyunsaturated Free Fatty Acid
In Study 1, octadecadienoic acid was highly responsive in the OA group (p < 0.001), resulting in a
response factor 7-fold significantly higher than that of the control group (Table 4). The MET group
(p < 0.001) also had a 2-fold significantly higher response factor as compared with the control group
(Table 4). The octadecadienoic acid response factor in the OA group (2.96 ± 3.12) was also 2-fold
higher than that of MET group (1.07 ± 0.60). The HF group (p < 0.05) had significantly lower levels
of octadecadienoic acid as compared with the control and with the rest of the experimental groups
(Table 4). The OA + HF group (0.43 ± 0.58) and MET + HF group (0.51 ± 0.53) were not distinctively
different from each other and were also not statistically different from the control group (Table 4).
Table 4. Octadecadienoic acid response factor (Ra) from rats in studies 1 and 2 of the experiment.
Experimental Groups Study 1 (Mean (Ra)± SD) Study 2 (Mean (Ra)± SD)
DW 0.35 ± 0.33 0.43 ± 0.58
OA 2.96 ± 3.12 *** 1.78 ± 1.06 ***
MET 1.07 ± 0.60 *** 0.75 ± 0.58
HF 0.08 ± 0.09 * 0.00 ± 0.00
OA + HF 0.43 ± 0.58 0.24 ± 0.17
MET + HF 0.51 ± 0.53 0.20 ± 0.15
Data of the octadecadienoic acid response factor (Ra) were calculated in R statistics and presented as mean ± sd
(n = 5). In phase 1, student’s t-test p-values were as follows; OA versus DW p < 0.001 (***), MET versus DW p < 0.001
(***) and HFruD versus DW p < 0.05 (*). In phase 2, OA versus DW p < 0.001 (***).
In Study 2, only the OA group was statistically significantly higher than the control group
(p < 0.001), the MET group (0.75 ± 0.55) was higher than the control group (0.43 ± 0.58) but not
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significant (Table 4). In the HF group, there was no octadecadienoic acid detected (Table 4). The OA
+ HF (0.24 ± 0.17) and MET + HF (0.21 ± 0.15) groups were not distinctively different from each
other and were both lower than the control group but not significant (Table 4). When the Study 1
octadecadienoic acid response factor was compared with that of Study 2, the experimental groups that
were statistically significantly different from each other were the OA, HF, OA + HF and MET + HF
groups (OA p < 0.01, HF p < 0.05, OA + HF p < 0.05 and MET + HF p < 0.05). The control group response
factor of study 2 (0.43 Ra) was slightly higher than that of Study 1 (0.35 Ra) (Table 4). There was a
statistically significant difference in the response factor of octadecadienoic acid from all studies of the
experiment (p < 0.01). The polyunsaturated free fatty acid was consistently highly responsive in the
OA and MET groups. OA + HF and MET + HF groups were higher than that of HF, but not distinctive
from one another. The OA diet promoted the accumulation of polyunsaturated free fatty acids in the
body more than the MET diet did.
2.5. Effects of Neonatal OA and MET Treatment on the Expression of Glut-4
In Study 1, the MET group (p < 0.001) glut-4 expression was 4-fold significantly higher than that
of the control group and in the OA group (p < 0.01), it was 3-fold significantly higher than the control
group (Figure 3A). Moreover, the OA + HF (p < 0.01) and MET + HF (p < 0.05) groups were also higher
than the control group by 2.5-fold and 2-fold (Figure 3A).
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Figure 3. Glut-4 gene expression in the skeletal uscle of rats in study 1 ( ) and study 2 (B) of the
experi ent, in hich each group as co pared ith the control (D ) (n = 3); p < 0.05 (*), p < 0.01 (**)
and p 0.001 (***).
In Study 2 experiment, glut-4 expression from the OA, MET (p < 0.05), OA + HF and MET + HF
groups were higher than the control group, but were all lower than that of Study 1 (Figure 3A,B).
Glut-4 expression in the HF group was lower than that of the control and lower than the rest of the
experimental diet groups (Figure 3A,B). The HF group suppressed the expression of glut-4 gene in
both studies 1 and 2 of the experiment. The MET experimental diet increased the expression of glut-4
better than OA experimental diet in both study 1 and 2 experiments. In both studies, the expression of
glut-4 gene was higher in the MET group and the OA group (Figure 3A,B).
2.6. Effects of Neonatal OA and MET Treatment on the Expression of Nrf-1
There was a 3.9-fold increase in the expression of nrf-1 in the OA (p < 0.001) group and an increase
of 4-fold in the MET group (p < 0.001), in the Study 1 experiments (Figure 4A). The OA + HF (p < 0.01)
had an expression of nrf-1 at about 2.5-fold, whilst MET + HF group (p < 0.01) had about 3-fold increase
as compared with the control group (Figure 4A).
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In the Study 2 experiments, the overall expression of nrf-1 was lower than 1.5 expression ratio, with
the OA, MET, OA + HF and MET + HF groups being higher than that of the control group (Figure 4B).
In the HF group (p < 0.05), the expression of nrf-1 was significantly suppressed to 0.78 expression ratio
in Study 1 whereas in Study 2 it was suppressed to 0.51 expression ratio (Figure 4A,B). As a result,
the HF group decreased the nrf-1 expression in both studies of the experiment. However, OA and MET
both increased the expression of nrf-1, with the expression of MET group being the highest in study
1 and OA dietary group being the highest in Study 2 (Figure 4A,B). Moreover, the MET + HF nrf-1
expression was higher than that of OA + HF in both studies 1 and 2 of the experiment (Figure 4A,B).
2.7. Effects of Neonatal OA and MET Treatment on the Expression of Acc-1
In the sub-acute study of the experiment, acc-1 expression was decreased in the OA group by
about 1-fold, in MET group by 1-fold and in OA + HF group by 0.1-fold from that of the control group
(Figure 5A). The MET + HF group was about 0.16 higher than the control (Figure 5A). In both Study 1
and Study 2, the HF group (p < 0.05) had a significantly increased expression, of about 1-fold higher
compared to the control group (Figure 5A,B).
In Study 2 of the experiment, the expression of acc-1 from the OA, OA + HF and MET + HF groups
were about 1-fold higher than that of the control (Figure 5B). The MET dietary group also decreased
the expression of acc-1 gene (Figure 5B).
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Figure 5. Acc-1 gene expression in skeletal muscle samples of rats in study 1 (A) and study 2 (B) of the
experiment. Each group versus the control group (DW) (n = 3); p < 0.05 (*).
2.8. Effects of Neonatal OA and MET Treatment on the Expression of Fas
The expression of fas gene was about 1-fold lower than the control group in the OA group,
whereas in the MET + HF it was 0.9 lower than the control group in Study 1 of the experiment
(Figure 6A). The OA + HF (p < 0.05) and MET + HF (p < 0.05) groups had an expression of fas of about
8-fold and 5-fold significantly lower than that of the control group (Figure 6A).
Molecules 2018, 23, x FOR PEER REVIEW  8 of 18 
Molecules 2018, 23, x; doi: www.mdpi.com/journal/molecules 
Figure 5. Acc-1 gene expression in skeletal muscle samples of rats in study 1 (A) and study 2 (B) of 
the experiment. Each group versus the control group (DW) (n = 3); p < 0.05 (*). 
In Study 2 of the experiment, the expression of acc-1 from the OA, OA + HF and MET + HF 
groups were about 1-fold higher than that of the control (Figure 5B). The MET dietary group also 
decreased the expression of acc-1 gene (Figure 5B). 
2.8. Effects of Neonatal OA and MET Treatment on the Expression of Fas 
The expression of fas gene was about 1-fold lower than the control group in the OA group, 
whereas in the MET + HF it was 0.9 lower than the control group in Study 1 of the experiment 
(Figure 6A). The OA + HF (p < 0.05) and MET + HF (p < 0.05) groups had an expression of fas of about 
8-fold and 5-fold significantly lower than that of the control group (Figure 6A). 
In Study 2 of the experiment, the expression ratio of fas in the OA group (p < 0.05) was 
significantly decreased by 3-fold, whereas the expression ratio in both OA + HF and MET + HF 
groups were just 1-fold less than that of the control group (Figure 6B). However, in Study 1 the 
expression of fas was about 14-fold lower than of the control in the OA + HF group, and that of the 
MET + HF group was 8-fold lower (Figure 6A). The HF group increased the expression of FAS in 
both studies 1 and 2 of the experiment (Figure 6A,B). 
 
Figure 6. Fas gene expression in the skeletal muscle of rats in Study 1 (A) and Study 2 (B) of the 
experiment. Each group was compared with DW (control group) (n = 3); p < 0.05 (*). 
2.9. Effects Neonatal OA and MET Treatment on Expression of cpt-1 
The OA dietary group increased the expression of cpt-1 gene 5.6-fold higher than that of the 
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control group (Figure 7A). Both the OA + HF (p < 0.05) and MET + HF (p < 0.05) increased the 
expression of cpt-1 to about 2-flod of the control group (Figure 7A). In both studies 1 and 2 of the 
experiment, the HF dietary group suppressed the expression of cpt-1to about a half of the control 
group (Figure 7A,B). In Study 1, the OA + HF and MET + HF groups had a 2-fold increased 
expression ratio of cpt-1 compared to the control and a 4-fold increase compared to the HF group 
(Figure 7A). 
In Study 2, the expression of cpt-1 was increased over 2-fold in the OA (p < 0.05) and MET (p < 
0.05) groups compared to the control group (Figure 7B). The OA + HF and MET + HF groups had a 
slightly increased expression of cpt-1 as compared to the control group, but about a 2-fold increase 
compared to the HF group (Figure 7B). The MET and MET + HF groups had a higher expression of 





































































Fig re 6. Fas ge e ex ressio i t e skeletal scle of rats i St y 1 ( ) a St y 2 ( ) of t e
e eri e t. ac r as c are it (c tr l ro ) (n = 3); p 0.05 (*).
In S udy 2 of the experiment, th expression ratio of fas in he OA group (p < 0.05) was significantly
decreased by 3-fold, whereas the expression ratio in both OA + HF and MET + HF groups were just
1-fold less than that of the control group (Figure 6B). However, in Study 1 the expression of fas was
about 14-fold lower than of the control in the OA + HF group, and that of the MET + HF group was
8-fold lower (Figure 6A). The HF group increased the expression of FAS in both studies 1 and 2 of the
experiment (Figure 6A,B).
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2.9. Effects Neonatal OA and MET Treatment on Expression of Cpt-1
The OA dietary group increased the expression of cpt-1 gene 5.6-fold higher than that of the
control group, whereas the MET dietary group increased the expression to about 5-fold of the control
group (Figure 7A). Both the OA + HF (p < 0.05) and MET + HF (p < 0.05) increased the expression of
cpt-1 to about 2-flod of the control group (Figure 7A). In both studies 1 and 2 of the experiment, the HF
dietary group suppressed the expression of cpt-1to about a half of the control group (Figure 7A,B).
In Study 1, the OA + HF and MET + HF groups had a 2-fold increased expression ratio of cpt-1
compared to the control and a 4-fold increase compared to the HF group (Figure 7A).Molecules 2018, 23, x 9 of 18 
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Figure 7. Cpt-1 gene expressi in the skeletal uscle of rats in Study 1 (A) and Study 2 (B) of the
experiment. Each group was compared with DW (control group) (n = 3); p < 0.05(*) and p < 0.0 1 (* ).
In Study 2, the expression of cpt-1 was increased over 2-fold in the OA (p < 0.05) and MET (p < 0.05)
groups compared to the control group (Figure 7B). The OA + HF and MET + HF groups had a slightly
increased expression of cpt-1 as compared to the control group, but about a 2-fold increase compared
to the HF group (Figure 7B). The MET and MET + HF groups had a higher expression of the cpt-1 gene
more than their comparable dietary groups OA and OA + HF (Figure 7B).
2.10. Effects Neonatal OA and MET Treatment on Expression of Glut-5
In study 1, there was a 2-fold increase in the expression of glut-5 in the rats that received neonatal
OA (p < 0.05), MET (p < 0.05) and OA + HF compared to the control groups increased the expression
of glut-5 to 2-fold of the control group in Study 1 (p < 0.05; Figure 8A). The MET + HF group only
increased the expression of glut-5 just 0.4 ratio over the control group (p < 0.05; Figure 8A). In both
studies 1 and 2 of the experiment, the HF dietary group decreased the expression of glut-5 to half of
the control group (Figure 8A,B). OA + HF group increased the expression of glut-5 to 5-fold, whereas
MET + HF increased it to 3-fold compared to the HF group (Figure 8A).
In the long term study of the experiment, the expression of glut-5 gene was increased to 5-fold in
the OA (p < 0.001) group and to 6-fold in the MET (p < 0.001) group compared to the control group
(Figure 8B). The OA + HF (p < 0.05) increased the expression of glut-5 to over 2.5-fold of the control,
whereas the MET + HF (p < 0.01) group increased it to over 3.5-fold (Figure 8B). Furthermore, OA +
HF increased glut-5 expression to 6-fold of the HF group and MET + HF group increased it to 9-fold
the ratio of HF group (Figure 8B).
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2.11. Effects of Neonatal OA and MET Treatment on the Expression of Aldolase-b
The OA group increased it to 4.5-fold (p < 0.001), MET group to 3.5-fold (p < 0.01), OA + HF group
to 2-fold (p < 0.05) and MET + HF group to 1.5-fold of the control in the sub-acute study (Figure 9A).
OA and OA + HF groups increased the expression of aldolase-b higher than their comparable dietary
groups MET and MET + HF in study 1 (Figure 9A). In Study 1 of the experiment, the HF group
decreased the expression of aldolase-b 2-fold lower than the OA + HF group and 1.5-fold lower than the
MET+HF group (Figure 9A).
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In the long term study, expression of aldolase-b was increased to about 3-fold in the OA (p < 0.01),
OA + HF (p < 0.01) and MET + HF (p < 0.01) as compared to the control group, whereas MET + HF
increased it to 4.5-fold of the control (Figure 9B). Moreover, in Study 2 aldolase-b expression was
decreased 3-fold lower than the OA + HF in the HF and decreased over 3-fold in the MET + HF
group (Figure 9B). However, in Study 2, MET (p < 0.001) and MET + HF (p < 0.01) increased aldolase-b
expression more than OA and OA + HF did (Figure 9B) Aldolase-b gene expression was suppressed
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in the HF group only and increased in the other four dietary experimental groups compared to the
control (Figure 9A,B).
3. Discussion
The energy expenditure of the body in the skeletal muscles requires glucose and lipid uptake,
performs thermogenic functions and other biochemical processes in the body [14]. In the long term
study of the experiment, the high fructose diet increased lipid storage in the triceps skeletal muscle
tissue which had an increased fat deposition due to neonatal metabolic programming. Our findings
showed that the rats that were treated with fructose in the neonatal period and later on in adulthood.
The HF group gained more weight than rats from the other treatment groups at the end of the study.
The excessive weight gain associated with high carbohydrate or fat diets impairs the ability of the
body to increase fat oxidation [15]. Previous studies have shown that fructose causes the deposition of
lipids into the skeletal muscles of both rats and humans [16,17].
Fructose consumption is known to induce metabolic effects associated with increased fat
deposition [17] as we have confirmed with our experimental rats that were fed with HF,
which eventually results in the development of obesity and metabolic syndrome. The rats in the
HF group stored more fat as compared to most of the rats from the other groups. The metabolic effects
of immoderate adiposity are exerted through the release of free fatty acids into peripheral and other
tissues of the body [15].
In the sub-acute study, our findings showed metformin to be effective in reducing lipid storage in
the MET + HF group. Similarly, in the long term (Study 2) experiments, metformin was shown to reduce
lipid storage as seen in the group that received neonatal treatment with MET. Metformin treatment
has also been found to reduce symptoms associated with obesity and metabolic syndrome in male
mice [9].
Stearic acid was higher in the HF group, which is the group where obesity/metabolic dysfunctions
were induced. These suggest that HF promotes accumulation of saturated free fatty acids in the body.
As shown in the study, the elevated level of stearic acid could be responsible for the fructose-induced
suppression of the glut-4, nrf-1, cpt-1 and ppary genes. Saturated FFAs directly down-regulate the
activity of glut-4 and ppary genes [18]. Moreover, it was previously reported that a high- fructose diet
causes suppression of the glut-4 and glut-2 gene expressions and this is dependent on both the diet and
age at which the diet is administered [19,20]. However, in this study there were no differences in the
suppression of glut-4 between neonatal fructose treatments and adulthood fructose administration.
We also showed that neonatal fructose consumption resulted in higher terminal body mass (Study
2 only) and saturated lipid accumulation within the skeletal muscle tissues (both studies 1 and 2 of
the experiment). The development of long-term health risks such as obesity and diabetes are often a
result of diets introduced to offspring during the critical window of developmental plasticity [21–23].
As such, administration of fructose in the neonatal period resulted in the development of health
outcomes associated with metabolic syndrome in rats that further received dietary fructose as adults.
Stearic acid was the lowest in both OA + HF and MET + HF, suggesting that the OA and MET
prevented the fructose induced accumulation of the saturated fatty acid in the body in both studies
of the experiment. It has been reported that stearic acid and other long chain saturated FFAs in
the high fat diet were responsible for suppression of glut-4 gene [19]. Dodecanoic, myristic and
palmitic saturated FFAs have also been shown to increase the risk factors of metabolic syndrome [24].
Polyunsaturated FFAs are important to the body and are acquired through dietary supplements as
the body cannot synthesize them. Octadecadienoic acid, which is commonly known as lenoleic acid
was a polyunsaturated free fatty acid detected in the samples by the GC-MS. Octadecadienoic acid is a
long chain 18-carbon compound polyunsaturated FFA. The levels of oleic acid and octadecadienoic
acid (unsaturated FFAs) were high in groups that received either OA and MET alone or a combination
of both. In this study, supplementation with OA in the neonatal period promoted the accumulation
of monounsaturated fatty acid in the body. Free fatty acids increase fat oxidation and glucose
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utilization [8]. Free fatty acids and glycerol are packaged in and transported by albumin from stored
fats to be oxidized through major pathways such as the β-oxidation pathway, which also occurs
in the mitochondria of skeletal muscles [25,26]. Monounsaturated FFAs; palmitoleic acid and oleic
acid have also been found to have positive effects on health outcomes associated with metabolic
syndrome [24,27].
Skeletal muscle tissue is a vital site for major glucose consumption, especially following a meal [23].
As such, glucose is transported into the tissue through an insulin stimulated facilitated diffusion by
glut-4 [28–31]. In this study, the administration of both OA and MET in fructose fed rats increased the
activity of glut-4, cpt-1 and nrf-1 genes. In order to achieve higher levels of glut-4 expression within the
skeletal muscles; transcription factors such as those belonging to the MEF2 domain, and ppary and
nrf-1 are required as glut-4 gene expression is controlled at the transcriptional level [19]. Ppary controls
the expression of glut-4 transporter in skeletal muscle cells as it binds to MEF2C and activates it [32].
Higher expressions of the nrf-1 gene increased the expression of glut-4 gene, thereby increasing glucose
transport capacity into the skeletal muscles [32]. As such, the high levels of both nrf-1 and glut-4 in our
study confirms that glucose was being metabolized in the skeletal muscles from groups that had OA,
MET, OA + HF and MET + HF in both studies of the experiment.
The gene expression of both fas and acc-1 were suppressed in the OA, MET, OA + HF and
MET + HF in both the phase 1 and 2 experiments. However, in the HF group, the expressions of fas
and acc-1 were increased. When animals are well fed on carbohydrates, fatty acid oxidation is lowered
by regulatory hormones such as insulin, but fatty acid synthesis is increased [25]. This suggests that
the HF dietary groups promoted FFA synthesis in the skeletal muscle cells. Phosphorylation of acc-1 by
AMPK decreases acc activity and malonyl-CoA content in rats [33–35]. Studies have shown that fatty
acid synthesis is also regulated through long-term hormonal regulation and or short-term substrate
availability where the presence of polyunsaturated FFAs in the diet decreases the concentration of
acc-1 and fas [18]. Moreover, in this study, the presence of polyunsaturated FFAs in the OA, MET, OA +
HF and MET + HF groups correlated with the decreased expression levels of acc-1 and fas.
Findings from the current study showed that cpt-1 gene was highly expressed in both OA and
MET groups and was suppressed in the HF group. Cpt-1 catalyzes the rate limiting step in skeletal
muscle fatty acid oxidation, in which decreased cytosolic long chain fatty acid Co-A results in the
increase of the activity of acc-1, where malonyl Co-A is phosphorylated and decreases the activity of
cpt-1 in which long acid chain fatty acid carnitine is ceased to be produced and will not be transferred
to the mitochondria for oxidation [7].
Glut-5 isoform gene is another hexose transporter found in the body. Although glut-5 is not highly
abundant in the skeletal muscle tissues, it has high affinity for fructose and low affinity for glucose,
therefore it is important for both fructose and glucose homeostasis. After consumption of high fructose
diet, fructose is efficiently metabolized by ketohexokinase into fructose-1 phosphate and then cleaved
by aldolase-b into dihydroxyacetone phosphate and glyceraldehyde [16,17,36]. Dihydroxyacetone
phosphate can directly enter gluconeogenesis; whereas glyceraldehyde is phosphorylated into
glyceraldehyde-3 phosphate [17,36]. Glyceraldehyde-3 phosphate can either be used for glycolysis,
gluconeogenesis, or enter the pentose phosphate pathway and be metabolized into acetyl-CoA so that
it can be used for liponeogenesis [17,36].
There was a decreased expression of glut-5 in the HF group and this was associated with high
levels of saturated FFAs. The glut-5 gene expression was also high in the OA, MET, OA + HF and
MET + HF treated groups. Over expression glut-5 in non-insulin dependent diabetes is associated with
increased fructose absorption [23,36]. In this study, over expression of glut-5 could have also been
influenced by the rate at which fructose was metabolized. This correlated to the increased expression
of aldolase-b in OA, MET, OA + HF and MET + HF groups when compared with normal control and
HF groups. However, the suppression of both glut-5 and aldolase-b in the HF suggests that HF could
lead to fructose malabsorption.
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4. Materials and Methods
4.1. Ethical Clearance
The experiments were conducted on 96 female Sprague Dawley pups that were housed in the
Central Animal Services at the University of the Witwatersrand. Ethical clearance for animal use was
granted by the Animal Ethics Committee of the University of the Witwatersrand (Ethics Screening
Number 2014/47/D).
4.2. Experimental Design
The study was conducted in two main experimental studies, a sub-acute study and a long term
study. Study 1 of the experiment was between postnatal days 7–14. The seven-day old pups were
randomly assigned to the following treatment groups: control—distilled water (DW) and 0.5% (v/v)
dimethyl sulphoxide, oleanolic acid (60 mg/kg) (purity > 99%) [37] dissolved in 0.5% (v/v) dimethyl
sulphoxide, metformin (500 mg/kg) (purity > 98%) [38] 0.5% (v/v) dimethyl sulphoxide, high fructose
solution (HF; 20% (w/v)—dissolved in 0.5% (v/v) dimethyl sulphoxide, oleanolic acid (OA) + high
fructose diet (OA + HF), and metformin + high fructose diet (MET + HF). Treatments were administered
once daily via oral gavage (10 mL/kg body weight) between 09:00–10:00 a.m. The pups were allowed
to continue nursing with their dams freely during the experimental period. The dosages of oleanolic
acid, metformin and high fructose died were based on the less toxic levels obtained from previous
studies using these doses. On PD 14, the rat pups were euthanized and samples collected. The dams
were returned to stock. In the second study of the experiment, the rats were weaned onto normal rat
chow and plain drinking water on PD21. The pups were then housed individually from PD 22 in cages
where they had ad libitum access to rat chow and plain drinking tap water until PD112.
4.3. Terminal Procedure and Sample Collection
On PD 112, the rats were then euthanized by an intra-peritoneal injection of sodium pentobarbital
(200 mg/kg body mass; Eutha-naze® (Bayer Corporation, Johannesburg, South Africa). The triceps
skeletal muscles were dissected out, placed in cryovials, then snap frozen in liquid nitrogen and stored
at −80 ◦C freezer until analyses.
4.4. Lipid Extraction, Purification and Identification by Gas Chromatography-Mass Spectrometry
Lipid extraction and purification from the skeletal muscle samples from study 1 and 2 was
performed according to a modified method described by [39]. Briefly, the snap frozen tissue samples
were taken from the −80 ◦C and placed on ice. Thereafter, the muscle tissue was cut from each
sample with a clean scalpel blade and 50 mg was weighed. Microcentrifuge tubes were used to place
the 50 mg muscle tissues. An internal standard (IS) mixture (Table 5) was prepared and added to
the weighed muscle tissue. The IS consists of methanol, water and chloroform. Steel beads were
then added to the sample mixture and the samples were placed on a Retch M400 vibration mill for
homogenization. This was followed by the removal of steel beads from the sample, where the sample
mixture was transferred into a new clean tube. The after homogenization, the internal standard mixture
(IS) was added into the sample (Table 5), then vortexed for 60 s using the Vortex-2 Genie machine
(Vortex-Genie® 2, Scientific Industries, Inc. Bohemia, New York, NY, USA). After that the sample
mixture was then centrifuged for 10 min at 2000× g at 4 ◦C. This resulted in a phase separation, with
the clear polar layer at the bottom and the milky apolar layer at the top of the muscle pellet. Both polar
and apolar samples were used for analysis, where in each sample 725 µL of polar sample was used
and 400 µL of apolar sample was used and transferred into Agilent vials (Table 5). Each sample had
five replicates. The samples were then dried under nitrogen. An oximation solution was then prepared
by dissolving 200 mg of methoxyamine into 10 mL of pyridine. In each dried sample, 50 µL of the
oximation solution was added followed by a 60 s vortexing. The samples were then placed at room
temperature for an hour. This was followed by the addition of 50 µL of bistri fluoacetamide (BSTFA),
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which contained 1% of trimethylsilyl chloride (TMCS) and then incubated for one hour at 40 ◦C. An
external standard was then prepared using 50 µL of 30 µg/mL eicosane in hexane, which was added
into the agilent vials inserts of each sample before running the GC-MS analysis.
Table 5. Standard Internal Mixture.
Internal Standard Mix (IS)
Weight (mg) Methanol (µL) Water (µL) IS (µL)
50 400 75 50
After Homogenization
Water (µL) Chloroform (µL) Total polar (~µL) Total apolar (~µL)
200 400 725 400





where ma is the mass of the lipid analyte of the free fatty acid a and Aa is the corresponding peak area
of the free fatty acid a and Ra is the Response Factor or the Peak Area Ratio of the free fatty acid a.
4.5. RNA Extraction
Samples were randomly selected from rats in Study 1 and Study 2 experimental groups, and a
total of 12 samples were used per extraction. From each sample, muscle tissue was crushed in a mortar
with a pestle using liquid nitrogen and 200 mg was weighed on a scale. The weighed tissue was
then transferred into a 1.5 mL tube and dissolved in a 1 mL Trizol (TRIzolTM Reagent, Thermo Fisher
Scientific Inc., Waltham, MA, USA). This was followed by homogenization and incubation on ice for
5 min, and then centrifugation at 12,000× g at 4 ◦C for 15 min. Trizol was then discarded from the
sample homogenate. Chloroform (200 µL) was added into the sample homogenate using a pipette,
then incubated on ice for 15 min. Thereafter, the sample homogenate was centrifuged at 12,000×
g for 15 min in order to achieve phase separation. The aqueous phase was then transferred into a
2 mL tube. Isopropanol (0.5 mL) was used to precipitate the RNA, followed by incubation on ice
for 10 min. The sample was then centrifuged for 10 min at 12,000× g at 4 ◦C. After centrifugation,
the supernatant was removed from the sample and the RNA sample pellet was air dried. RNase free
water (20 µL) was then used to dissolve the extracted RNA pellet. This was followed by determination
of RNA concentration and ratio using a nanodrop machine (NanoDropTM Lite Spectrophotometer,
Thermo Fisher Scientific Inc.).
4.6. Gel Electrophoresis
Gel preparation involved weighing 1.5 g of agarose gel on a scale and dissolving it in 150 mL of
tris acetate buffer (1× TAE buffer), which was prepared at 500 mL TAE buffer. The solution was then
microwaved for 60 s to dissolve the gel. The gel solution was cooled at room temperature to 50 ◦C
temperature. Ethidium bromide (2 µL) was then added to the gel solution. The gel was poured into
the electrophoresis chamber, in which sample wells were created using the comp. One extracted RNA
sample from each experimental group (DW, OA, MET, HF, OA + HF and MET + HF) was randomly
selected to be used for the gel electrophoresis, in which a total of six samples were used. Two were
from Study 1 and three from Study 2 (DW and MET = study 1 and OA, HF, OA + HF and MET + HF =
study 2). A staining procedure then followed, were in each sample a pipette was used to obtain 1 µL of
RNA, which was mixed with a 1 µL of purple dye. RNA ladder standard marker was also used at a 1:1
ratio with the purple dye. The RNA marker was added into the first sample well, followed by DW, OA,
MET, HF, OA + HF and MET + HF in that order. The rest of the TAE buffer solution was added into
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the electrophoresis chamber as running buffer. The gel was then run on an electrophoresis chamber for
80 min at 60 volts. RNA bands were then visualized at the SYBR Green Filter at 500–600 m (Figure 10).
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4.7. cDNA Synthesis
DNA was synthesized from RNA samples using the Superscript VILO cDNA synthesis kit
(iScriptTM select cDNA synthesis kit, Bio-Rad Laboratories, Inc., Foster city, CA, USA). This involved
determining the RNA concentration needed for synthesizing cDNA, which varied per sample as it
depended on the RNA concentration observed from the Nanodrop machine. A master-mix for each
single reaction was prepared using 4 µL of 5× VILO reaction mix, 2 µL 10× Superscript enzyme mix,
sample RNA of up to 2.5 µg and DEPC-treated water of up to 20 µL. The mixture was then incubated
at 25 ◦C for 10 min. Incubation was repeated at 42 ◦C for an hour. The reaction was terminated at 85
◦C incubation for 5 min.
4.8. Quantitative Real Time PCR (RT-qPCR)
Quantitative Real Time PCR (qPCR) was performed for seven genes, namely; acc-1, cpt-1, fas, nrf-1,
glut-4, glut-5 and aldolase-b. For each gene, three replicates per sample from each experimental group
were analyzed. Firstly, 1 µL of sample cDNA was pipetted from the sample and diluted with 19 µL
of RNase free water to get a 20 µL volume. From the diluted cDNA sample, 1:20 ratio of cDNA to
RNase free water was pipetted into new three qPCR tubes. The gene of interest forward and reverse
primers and those of reference gene master-mix were prepared separately, with SYBR green master-mix.
Primers used are provided in Table 6.
Table 6. Specific primers used for each gene.
Gene For:
Primers Orientation
Forward 5′–3′ Reverse 3′–5′
cpt-1 GCA AAC TGG ACC GAG AAG AG TCC ATG AGG GAT GGA CTC TC
nrf-1 GTT GGA TCC CTC TCA CCC ATT G CCA AGT CGA GAC TTA ATT CC
acc-1 AGG AGG GAA GGG AAT CAG AA TGT GCT GCA GGA AGA TTG AC
Fas GCT TTG CTG CCG TGT CCT TCT GTG TCT GCT GGG GTC CTC GTT
glut-4 GCA GCG AGT GAC TGG AAC A CCA GCC ACG TTG CAT TGT AG
glut-5 CCA GAG AAG CAT GGA GCA AGG ATG ACC CAA AGG CAG
Aldolase-b GCC ACC TCA CAC AGC TTC TG TCG GTG AGC CAT GAT GAC A
Actin AGC CAT GTA CGT AGC CAT CC CTC TCA GCT GTG GTGGTG AA
Gapdh GCA CAG TCA AGG CCG AGA AT GCC TTC TCC ATG GTG GTG AA
The primer stocks were diluted according to the manufacturer’s guide. From the master-mix
of each gene, 7 µL was pipetted into the qPCR sample tubes. Thereafter, cDNA (3 µL) was added
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into the qPCR sample tube in order to achieve a 10 µL final volume. The samples were loaded into
the RT-qPCR machine for analysis in a specific order of choice. The RT-qPCR was set to run using
instructions provided by the manufacturer as the instrument user guide, in which a standard cycling
mode was used.
4.9. Statistical Analysis
Data was expressed as mean ± standard deviation (SD). A one way ANOVA was used to
determine differences in means from different experimental groups. All statistical analyses were
performed in R version 3.4.0 statistical software (R Development Core Team, Auckland, New Zealand)
Level of significance was set at p ≤ 0.05.
5. Conclusions
The present study showed that neonatal intake of oleanolic acid and metformin almost equally
prevented the fructose induced metabolic dysfunction in the rats, sub-acutely and in the long term.
Though metformin is an already known drug that is used in the treatment of type 2 diabetes
across the globe, this study showed its ability to potentially prevent metabolic disorders when
administered during a period of developmental plasticity. In a similar vein, the study also showed
the efficacy of a plant-derived compound, oleanolic acid as prophylactic agent in the prevention of
metabolic dysfunction caused by high dietary fructose intake. These results show that there is need to
further develop strategies to identify candidate biologically active phytochemicals for use in critical
developmental windows for prophylactic interventions to help to reduce the occurrence of metabolic
diseases such as type2 diabetes and obesity.
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